LCZ696, the first ARNI, was recommended as a new drug in the 2018 Heart failure guidelines. The guidelines point out that patients with serum creatinine > 221?umol/L (2.5?mg/dl) or eGRF < 30?ml /(min·1.73 m2) are careful to use ARNI. It can be seen that the effect of ARNI on renal function is very important in the safety and efficacy of treatment. In this paper, the effects of LCZ696 on kidney were reviewed. The results showed that LCZ696 might cause a slight increase in UACR, but LCZ696 could slow down the decline of eGFR, delay the deterioration of renal function, lower blood pressure, improve renal pathology, and have good safety and tolerance.